We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -3.39% | 2.85 | 2.80 | 2.90 | 2.95 | 2.85 | 2.90 | 2,684,036 | 08:23:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 13.09M | -33.29M | -0.0429 | -0.66 | 22.88M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/11/2024 17:16 | When i sthe €1 million from Pediatruc studay to be received ?? | krp10 | |
15/11/2024 12:48 | Funny - Bobath is trying to troll me on GSK even though I'm apparently filtered and don't exist. Clearly lying is in the fabric of his personality | dplewis1 | |
15/11/2024 11:23 | RICHARD BOBARTH news article www.mirror.co.uk/new | antonagis | |
15/11/2024 11:22 | How many mugs are invested here? Do you all still feel confident in anything whatsoever PURCHASEATTHETOP (RICHARD BOBARTH) or his disciples such us ZEUS have to say? You were all warned and I was mocked by a couple of his disciples a few weeks ago when at 4.5p. Who is laughing now? He’ll continue to post all day every day until this is completely worthless and then move on to ramp another worthless stock. Check his posting history on every single stock he’s ever ramped since he joined ADVFN. | antonagis | |
15/11/2024 10:43 | “Although there had been some recovery in the share price to ca.5.Op, following the 3Q'24 trading update, the market has become more concerned about the continuing commercial risk and the debate about gross cash. This was exacerbated by the updated view that Shield needed to agree a share subscription for a minimum of $10m from its major shareholder, AOP Health, to get it to cashflow-breakeven. The market needs to see further benefits of the enlarged sales team in each sequential quarter in order to have the confidence to rerate the shares.” Seems accurate enough. Whether the extra risk means the share price should halve when the Rx seems just below $200 now when it was $119 a year ago and prescriptions have doubled in a year! The market seems to be assuming more failures by the new lesdership just like the Madison crew. Maybe not this time. | purchaseatthetop | |
15/11/2024 10:07 | Slide 10 had good info. $325k incoming from KYE with the Canadian launch scheduled for next quarter | zeus19 | |
15/11/2024 10:04 | Cheers Zeus. Seems pretty definite! “Shield is being proactive, extending its working capital financing from $10m to $15m and issuing $10m new shares to AOP, to manage the company through to cashflow-breakeven in 2H25.” “Sequential 3Q'24 Rx growth of 20%, to 43,500, was modestly below expectations (28%). Combined with the weak July selling price, sales, at $7.2m, were below our $7.9m forecast. However, the higher $192 selling price in the latter months of 3Q'24 is expected to be maintained throughout 4Q'24.” “Management is being very proactive in the management of gross cash in order to take the company through to cashflow-breakeven in 2H'25.” | purchaseatthetop | |
15/11/2024 09:38 | https://hardmanandco | zeus19 | |
15/11/2024 09:26 | Any feedback from Hardman & co investor forum event held on 14th Nov | krp10 | |
13/11/2024 20:30 | RICHARD BOBARTH with the same old line about an RNS. It’s priceless repetition on every board he’s been on since he joined ADVFN. | antonagis | |
13/11/2024 19:42 | Would be timely to have a funding RNS 7am tomorrow. | purchaseatthetop | |
13/11/2024 17:51 | Shield Therapeutics plcShield Therapeutics plc 5,423 followers5,423 followers 2h • Edited • 2 hours ago On 14 November, Anders Lundstrom, Interim CEO, and Santosh Shanbhag, CFO, will be joining the panel for the Hardman & Co Investor Forum. We look forward to discussing the impact of changes in the global markets on healthcare investments and exploring new growth avenues in the sector. Join us as we share our insights and connect with fellow investors and industry experts. Register now to participate, ask questions, and gain valuable insights here: | purchaseatthetop | |
12/11/2024 21:23 | Recruiting in Austin, Texas 22 applicants in a day. | purchaseatthetop | |
12/11/2024 20:54 | Certainly is.My Mum is early 70's. On blood pressure tablets. Got a blood test recently and her iron levels were 8. Should be between 10&30. The further we move away from the land and consume highly processed foods the more this will become a problem. | r9505571 | |
12/11/2024 17:35 | Quite a big potential market to grow into! CNN — You may have an iron deficiency and not even know it. A large proportion of adults in the United States – nearly 1 in 3 – may have one of two forms of iron deficiency, even if they don’t have a health condition for which they would be screened for it, such as anemia, heart failure or chronic kidney disease, a new study suggests. The study, published Tuesday in the medical journal JAMA Network Open, warns that iron deficiency may be a “widespread&rd | purchaseatthetop | |
12/11/2024 14:45 | Interesting comparisons between STX and CREO. So thanks to Parob for coming to the board to try to upset me. CREO have spent £157m if retained losses getting to losing £10m every six months. Overhead of £40m a year. Sales about £30m. No revenue growth. 47% gross margin. STX have spent about the same of retained losses getting to losing the same amount every six months. Overhead about the same. 250% revenue growth with similar revenue now. same gross margin. Likely £65m plus revenue 2025. STX market cap £21k CREO market cap £75m Certainly seems one is under or overvalued. Very similar in many ways. | purchaseatthetop | |
12/11/2024 12:46 | No you are lying AGAIN. I never said the growth rate is bad.I have been telling investors to be careful of you and your posts. | parob | |
12/11/2024 12:44 | PATT has starting knocking CREO so you can expect the price to start rising imo. Contra indicator. | parob | |
12/11/2024 12:35 | Actually if you want a real laugh, Parob is pumping CREO. Revenue static at £10m every six months Gross margin static at 47% Cash burn of £10m every six months. Going concern active with them relying on selling a part of their business “expected Q1 25” but subject to numbers of future uncertainties. And he thinks STX with its 250% growth rate is bad. | purchaseatthetop | |
12/11/2024 11:06 | I thought you had me filtered?Another lie. | parob | |
12/11/2024 10:58 | I don’t know why Parob is here posting when I had never posted anything on any of his boards. However, that has now changed. Parob can get used to me doing exactly the same to him. Makes it even don’t you think. | purchaseatthetop | |
12/11/2024 10:30 | Large sells going through under the bid price now.Is PATT still ramping? | parob |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions